Advertisement

Topics

AZD6244 in Treating Patients With Recurrent or Persistent Endometrial Cancer

2014-08-27 03:18:03 | BioPortfolio

Summary

RATIONALE: AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well AZD6244 works in treating patients with recurrent or persistent endometrial cancer.

Description

OBJECTIVES:

Primary

- To assess the activity of MEK inhibitor AZD6244, in terms of progression-free survival rate for ≥ 6 months after initiating therapy or objective response rate, in patients with recurrent or persistent endometrial carcinoma.

- To determine the nature and degree of toxicity of this regimen in these patients as assessed by NCI CTCAE v3.0.

Secondary

- To determine the duration of progression-free survival and overall survival of patients treated with this regimen.

Exploratory

- To explore the association between select biomarkers and response to MEK inhibitor AZD6244 (progression-free survival status > 6 months and objective tumor response), measures of clinical outcome (progression-free survival and overall survival), or disease status, including histologic cell type.

- To explore the relationship among a panel of biomarkers, including mutations and single nucleotide polymorphisms in BRAF, KRAS2, FGFR2, PI3KCA, AKT1, AKT2, AKT3, and PTEN as well as immunohistochemical expression of ERK, pERK, GSK3β, pGSK3β, PR-A, PR-B, pPR, ERα, ERβ, BRAF, KRAS, PTEN, EGFR, pEGFR, EGF, PELP1, and MTA1s.

OUTLINE: This is a multicenter study.

Patients receive oral MEK inhibitor AZD6244 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Blood and archived tumor tissue samples are collected for biomarker studies.

After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Study Design

Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment

Conditions

Endometrial Cancer

Intervention

MEK inhibitor AZD6244, laboratory biomarker analysis

Location

University of Colorado Cancer Center at UC Health Sciences Center
Aurora
Colorado
United States
80045

Status

Suspended

Source

National Cancer Institute (NCI)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:18:03-0400

Clinical Trials [3097 Associated Clinical Trials listed on BioPortfolio]

AZD6244 in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

RATIONALE: AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well AZD6244 works in treating p...

AZD6244 in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

RATIONALE: AZD6244 may stop the growth of cancer by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II clinical trial is studying how well AZD6244 works in treati...

AZD6244 in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

RATIONALE: AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well AZD624...

AZD6244 in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

This phase II trial is studying how well AZD6244 works in treating patients with papillary thyroid cancer that did not respond to radioactive iodine. AZD6244 may stop the growth of tumor c...

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. AZD6244 may s...

PubMed Articles [31678 Associated PubMed Articles listed on BioPortfolio]

Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells and in nude mice by attenuating HER3/Akt pathway activation.

The present study investigated the molecular mechanism by which the epidermal growth factor receptor (EGFR) inhibitor cetuximab enhances the antitumor activity of the mitogen-activated protein kinase ...

Association of BMI and height with the risk of endometrial cancer, overall and by histological subtype: a population-based prospective cohort study in Japan.

Evidence on the association between BMI, height, and endometrial cancer risk, including by subtypes, among Asian populations remains limited. We evaluated the impact of BMI and height on the risk of e...

Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis.

Recent epidemiological studies have investigated the associations between the use of bisphosphonates and the development of endometrial cancer and ovarian cancer; these studies have shown controversia...

Evaluation of complete blood count parameters to predict endometrial cancer.

Complete blood count parameters have been introduced to be diagnostic biomarkers for many cancer-related diseases associated with inflammatory process. The aim of our study was to detect whether there...

Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling.

Metformin recently gained traction as potential anti-endometrial cancer agent for its new applications. However, the underlying mechanisms of the anti-cancer effect of metformin in the endometrial can...

Medical and Biotech [MESH] Definitions

Neoplasms of the endometrial stroma that sometimes involve the MYOMETRIUM. These tumors contain cells that may closely or remotely resemble the normal stromal cells. Endometrial stromal neoplasms are divided into three categories: (1) benign stromal nodules; (2) low-grade stromal sarcoma, or endolymphatic stromal myosis; and (3) malignant endometrial stromal sarcoma (SARCOMA, ENDOMETRIAL STROMAL).

A hereditary disease characterized by multiple ectodermal, mesodermal, and endodermal nevoid and neoplastic anomalies. Facial trichilemmomas and papillomatous papules of the oral mucosa are the most characteristic lesions. Individuals with this syndrome have a high risk of BREAST CANCER; THYROID CANCER; and ENDOMETRIAL CANCER. This syndrome is associated with mutations in the gene for PTEN PHOSPHATASE.

The extension of endometrial tissue (ENDOMETRIUM) into the MYOMETRIUM. It usually occurs in women in their reproductive years and may result in a diffusely enlarged uterus with ectopic and benign endometrial glands and stroma.

Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.

Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant.

More From BioPortfolio on "AZD6244 in Treating Patients With Recurrent or Persistent Endometrial Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...


Searches Linking to this Trial